公开(公告)号：US20150232420A1

公开(公告)日：2015-08-20

申请号：US14429288

申请日：2013-09-19

申请人： Celia DOMINGUEZ ,  Michael PRIME ,  Richard MARSTON ,  Frederick A. BROOKFIELD ,  Stephen M. COURTNEY ,  Douglas MACDONALD ,  John WITYAK ,  Christopher John YARNOLD ,  Darshan VAIDYA

发明人： Celia Dominguez ,  Michael Prime ,  Richard Marston ,  Frederick A. Brookfield ,  Stephen M. Courtney ,  Douglas Macdonald ,  John Wityak ,  Christopher John Yarnold ,  Darshan Vaidya

IPC分类号： C07C271/22 ,  C07D207/06 ,  C07D213/74 ,  C07D205/04 ,  C07D211/08 ,  C07D295/185 ,  C07D223/04

CPC分类号： C07C271/22 ,  C07D205/04 ,  C07D207/06 ,  C07D207/16 ,  C07D211/08 ,  C07D211/16 ,  C07D213/72 ,  C07D213/74 ,  C07D223/04 ,  C07D277/42 ,  C07D295/18 ,  C07D295/185 ,  C07D309/08 ,  C07D401/12

摘要： Certain compounds and pharmaceutically acceptable salts are provided herein. Also provided are pharmaceutical compositions comprising at least one compound or pharmaceutically acceptable salt therein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain disease states responsive to the inhibition of transglutaminase TG2 activity are described. These disease states include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound or pharmaceutically acceptable salt thereof as a single active agent or administering at least one compound or pharmaceutically acceptable salt thereof in combination with one or more other therapeutic agents.

摘要翻译： 本文提供了某些化合物和药学上可接受的盐。 还提供了包含至少一种化合物或其药学上可接受的盐的药物组合物和一种或多种药学上可接受的载体。 描述了治疗患有某种疾病状态的患者对抑制转谷氨酰胺酶TG2活性有反应的方法。 这些疾病状态包括神经变性疾病如亨廷顿病。 还描述了治疗方法，包括给予至少一种化合物或其药学上可接受的盐作为单一活性剂，或者与一种或多种其它治疗剂组合施用至少一种化合物或其药学上可接受的盐。

公开(公告)号：US08946197B2

公开(公告)日：2015-02-03

申请号：US13509783

申请日：2010-11-12

申请人： Celia Dominguez ,  John Wityak ,  Michael Prime ,  Stephen Martin Courtney ,  Christopher Yarnold ,  Frederick Brookfield ,  Richard Marston ,  Douglas Macdonald

发明人： Celia Dominguez ,  John Wityak ,  Michael Prime ,  Stephen Martin Courtney ,  Christopher Yarnold ,  Frederick Brookfield ,  Richard Marston ,  Douglas Macdonald

IPC分类号： A61K31/635 ,  C07C311/46 ,  C07D211/34 ,  C07D211/54 ,  C07D211/58 ,  C07D211/96 ,  C07D213/38 ,  C07D213/40 ,  C07D213/56 ,  C07D215/38 ,  C07D217/14 ,  C07D217/22 ,  C07D239/42 ,  C07D263/58 ,  C07D277/42 ,  C07D295/205 ,  C07D295/26 ,  C07D307/52 ,  C07D401/04 ,  C07D487/04 ,  C07D495/04

CPC分类号： C07C311/46 ,  C07C2601/14 ,  C07D211/34 ,  C07D211/54 ,  C07D211/58 ,  C07D211/96 ,  C07D213/38 ,  C07D213/40 ,  C07D213/56 ,  C07D215/38 ,  C07D217/14 ,  C07D217/22 ,  C07D239/42 ,  C07D263/58 ,  C07D277/42 ,  C07D295/205 ,  C07D295/26 ,  C07D307/52 ,  C07D401/04 ,  C07D487/04 ,  C07D495/04

摘要： Certain compounds and pharmaceutically acceptable salts are provided herein. Also provided are pharmaceutical compositions comprising at least one compound or pharmaceutically acceptable salt therein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain disease states responsive to the inhibition of transglutaminase TG2 activity are described. These disease states include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound or pharmaceutically acceptable salt thereof as a single active agent or administering at least one compound or pharmaceutically acceptable salt thereof in combination with one or more other therapeutic agents.

摘要翻译： 本文提供了某些化合物和药学上可接受的盐。 还提供了包含至少一种化合物或其药学上可接受的盐的药物组合物和一种或多种药学上可接受的载体。 描述了治疗患有某种疾病状态的患者对抑制转谷氨酰胺酶TG2活性有反应的方法。 这些疾病状态包括神经变性疾病如亨廷顿病。 还描述了治疗方法，包括给予至少一种化合物或其药学上可接受的盐作为单一活性剂，或者与一种或多种其它治疗剂组合施用至少一种化合物或其药学上可接受的盐。

公开(公告)号：US08889716B2

公开(公告)日：2014-11-18

申请号：US13466018

申请日：2012-05-07

申请人： Michael Prime ,  Stephen Martin Courtney ,  Richard Marston ,  Celia Dominguez ,  Douglas MacDonald ,  John Wityak

发明人： Michael Prime ,  Stephen Martin Courtney ,  Richard Marston ,  Celia Dominguez ,  Douglas MacDonald ,  John Wityak

IPC分类号： A61K31/445 ,  C07D211/96 ,  C07D409/12 ,  C07D205/04 ,  C07D405/12 ,  C07D405/14 ,  C07D207/48 ,  C07D401/14 ,  C07D401/12

CPC分类号： C07D205/04 ,  C07D207/48 ,  C07D211/96 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/12

摘要： Certain compounds and pharmaceutically acceptable salts are provided herein. Also provided are pharmaceutical compositions comprising at least one compound or pharmaceutically acceptable salt therein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain disease states responsive to the inhibition of transglutaminase TG2 activity are described. These disease states include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound or pharmaceutically acceptable salt thereof as a single active agent or administering at least one compound or pharmaceutically acceptable salt thereof in combination with one or more other therapeutic agents.

摘要翻译： 本文提供了某些化合物和药学上可接受的盐。 还提供了包含至少一种化合物或其药学上可接受的盐的药物组合物和一种或多种药学上可接受的载体。 描述了治疗患有某种疾病状态的患者对抑制转谷氨酰胺酶TG2活性有反应的方法。 这些疾病状态包括神经变性疾病如亨廷顿病。 还描述了治疗方法，包括给予至少一种化合物或其药学上可接受的盐作为单一活性剂，或者与一种或多种其它治疗剂组合施用至少一种化合物或其药学上可接受的盐。

公开(公告)号：US20130116216A1

公开(公告)日：2013-05-09

申请号：US13509783

申请日：2010-11-12

申请人： Celia Dominguez ,  John Wityak ,  Michael Prime ,  Stephen Martin Courtney ,  Christopher Yarnold ,  Frederick Brookfield ,  Richard Marston ,  Douglas Macdonald

发明人： Celia Dominguez ,  John Wityak ,  Michael Prime ,  Stephen Martin Courtney ,  Christopher Yarnold ,  Frederick Brookfield ,  Richard Marston ,  Douglas Macdonald

IPC分类号： A61K31/55 ,  A61K31/496 ,  C07D401/02 ,  A61K31/45 ,  C07D413/02 ,  C07D403/04 ,  A61K31/5377 ,  A61K31/495

CPC分类号： C07C311/46 ,  C07C2601/14 ,  C07D211/34 ,  C07D211/54 ,  C07D211/58 ,  C07D211/96 ,  C07D213/38 ,  C07D213/40 ,  C07D213/56 ,  C07D215/38 ,  C07D217/14 ,  C07D217/22 ,  C07D239/42 ,  C07D263/58 ,  C07D277/42 ,  C07D295/205 ,  C07D295/26 ,  C07D307/52 ,  C07D401/04 ,  C07D487/04 ,  C07D495/04

摘要： Certain compounds and pharmaceutically acceptable salts are provided herein. Also provided are pharmaceutical compositions comprising at least one compound or pharmaceutically acceptable salt therein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain disease states responsive to the inhibition of transglutaminase TG2 activity are described. These disease states include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound or pharmaceutically acceptable salt thereof as a single active agent or administering at least one compound or pharmaceutically acceptable salt thereof in combination with one or more other therapeutic agents.

公开(公告)号：US20120302539A1

公开(公告)日：2012-11-29

申请号：US13466018

申请日：2012-05-07

申请人： Michael Prime ,  Stephen Martin Courtney ,  Richard Marston ,  Celia Dominguez ,  Douglas Macdonald ,  John Wityak

发明人： Michael Prime ,  Stephen Martin Courtney ,  Richard Marston ,  Celia Dominguez ,  Douglas Macdonald ,  John Wityak

IPC分类号： A61K31/4468 ,  C07D405/12 ,  A61K31/453 ,  C07D207/48 ,  A61K31/40 ,  A61K31/4525 ,  C07D409/12 ,  A61K31/4535 ,  C07D401/12 ,  A61K31/454 ,  C07D405/14 ,  C07D205/04 ,  A61K31/397 ,  A61K31/4545 ,  C07D401/14 ,  A61K31/496 ,  C07D413/12 ,  A61K31/5377 ,  A61P25/28 ,  A61P1/16 ,  A61P13/12 ,  A61P25/00 ,  A61P35/04 ,  A61P35/02 ,  A61P35/00 ,  A61P37/00 ,  A61P29/00 ,  A61P19/02 ,  A61P17/06 ,  A61P9/00 ,  A61P9/10 ,  A61P3/10 ,  A61P17/10 ,  A61P27/12 ,  A61P27/10 ,  A61P21/00 ,  A61P17/02 ,  A61P1/00 ,  A61P25/14 ,  A61P25/16 ,  C07D211/96

CPC分类号： C07D205/04 ,  C07D207/48 ,  C07D211/96 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/12

摘要： Certain compounds and pharmaceutically acceptable salts are provided herein. Also provided are pharmaceutical compositions comprising at least one compound or pharmaceutically acceptable salt therein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain disease states responsive to the inhibition of transglutaminase TG2 activity are described. These disease states include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound or pharmaceutically acceptable salt thereof as a single active agent or administering at least one compound or pharmaceutically acceptable salt thereof in combination with one or more other therapeutic agents.

摘要翻译： 本文提供了某些化合物和药学上可接受的盐。 还提供了包含至少一种化合物或其药学上可接受的盐的药物组合物和一种或多种药学上可接受的载体。 描述了治疗患有某种疾病状态的患者对抑制转谷氨酰胺酶TG2活性有反应的方法。 这些疾病状态包括神经变性疾病如亨廷顿病。 还描述了治疗方法，包括给予至少一种化合物或其药学上可接受的盐作为单一活性剂，或者与一种或多种其它治疗剂组合施用至少一种化合物或其药学上可接受的盐。